|
Mar 15
|
US STOCKS-Wall St slides as inflation woes dampen rate-cut bets
|
|
Mar 15
|
Madrigal Can Market the First Drug for Obesity-Scarred Livers. The Stock Soars.
|
|
Mar 15
|
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
|
|
Mar 15
|
Madrigal, FDA approval in hand, outlines plan to sell MASH drug
|
|
Mar 14
|
Madrigal Stock Soars More Than 20% After FDA Approved First In MASH Treatment
|
|
Mar 14
|
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
|
|
Mar 14
|
Madrigal wins FDA approval of first drug for MASH
|
|
Mar 9
|
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
|
|
Mar 5
|
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
|
|
Mar 5
|
1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247?
|
|
Dec 19
|
Senior VP Robert Waltermire Sells 4,000 Shares of Madrigal Pharmaceuticals Inc (MDGL)
|
|
Dec 19
|
11 Stocks Insiders and Billionaires Are Crazy About
|
|
Dec 7
|
These 2 Stocks Could Be About to Soar: Are They Buys?
|
|
Nov 27
|
11 Best Upside Stocks To Buy Right Now
|
|
Nov 16
|
Baker Bros. Advisors LP Bolsters Position in Madrigal Pharmaceuticals Inc
|
|
Nov 15
|
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 10
|
Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health
|
|
Nov 10
|
Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer
|
|
Nov 7
|
Madrigal Pharmaceuticals Inc (MDGL) Reports Third Quarter 2023 Financial Results
|
|
Nov 6
|
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results
|